Sign In
Buy NXL
$0.533
-0.0175 (-3.18%)
At Close: Jun 03, 2026
U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant tra
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD Acquisition gives Nexalin control of AI-int
Publication reports statistically significant improvement in sleep quality following treatment with Nexalin's 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
09:35am, Wednesday, 22'nd Apr 2026
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 160-participant, triple-blinded, sham-controlled study designe
Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China
10:00am, Wednesday, 15'th Apr 2026
HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™
Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21
08:30am, Tuesday, 14'th Apr 2026
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin's differentiated, non-i
Critical Analysis: Algorhythm (NASDAQ:RIME) versus Nexalin Technology (NASDAQ:NXL)
01:59am, Thursday, 02'nd Apr 2026
Nexalin Technology (NASDAQ: NXL - Get Free Report) and Algorhythm (NASDAQ: RIME - Get Free Report) are both small-cap business services companies, but which is the superior stock? We will contrast the
Nexalin Technology, Inc. (NASDAQ:NXL) Short Interest Update
03:13am, Tuesday, 31'st Mar 2026
Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report) saw a significant decline in short interest in March. As of March 13th, there was short interest totaling 440,670 shares, a decline of 26.4% fr
150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment
Nexalin Participates in & Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for
EXCLUSIVE: Nexalin Launches AI-Powered Virtual Clinic For Brain Health For Home Settings
08:21am, Thursday, 05'th Feb 2026
Nexalin launched its AI-powered NeuroCare virtual clinic with UC San Diego, enabling at-home brain treatment, remote monitoring, and subscription-based care for Alzheimer's, mood disorders, and brain
HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)
Nexalin Technology (NASDAQ:NXL) Trading 1% Higher – Time to Buy?
02:44am, Friday, 23'rd Jan 2026
Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report)'s stock price traded up 1% during trading on Thursday. The company traded as high as $0.65 and last traded at $0.63. 53,433 shares traded hands
